BMO Investorline: “Vitalhub Corp provides technology to Health and Human Service providers, including Hospitals, Regional Health Authorities, Mental Health, Long-Term Care, Home Health, and Community and Social Services. Vitalhub solutions span the categories of Electronic Health Records (EHR), Case Management, Care Coordination, Patient Flow, Operational Visibility, and Mobile Apps. It operates in one segment for its operations related to healthcare information systems in the mental health, long-term care, community health service, and hospital sectors. Geographically, it's available in Canada, the United Kingdom, Australia, the USA, Western Asia, and the Rest of the world, and the majority of the revenue comes from the United Kingdom.”
1.
Statistics from various sources as of 2026-04-25:
Current price: $8.14
CAD
PE: 81.80
EPS: $0.10
Forward PE: 22.59
52 Week Range: $6.67 CAD
- $14.64 CAD
Market cap: $515M CAD
Price to Book (TTM): 1.86
Gross margin: 80.38%
Net Profit Margin:
5.61%
Return on Average Equity
(ttm): 2.98%
Total Cash (mrq): 119.18M
CAD
Total Debt (mrq): 2.51M
CAD
Current Ratio (mrq): 2.40
Book Value Per Share
(mrq): $4.21 CAD
Operating Cash Flow
(ttm): $8.32M CAD
----------
2.
Share price estimates as of 2026-04-25:
-
Yahoo’s 1-yr target: $12.62 CAD
-
LSEG rating: $12.63 CAD with 10 Buy (H $15.00
CAD – M $12.50 CAD – L $11 CAD)
-
Morningstar’s target value: $14.74 USD –
undervalue
-
TipRanks Ratings: $12.60 CAD with
consensus rating Strong Buy.
-
BMO Investorline: 4.8 by 10 brokers (1.00
Sell – 5.00 Strong Buy)
|
BayStreet.ca |
Analysis Change Analysis Change |
Rating Rating |
Target Price Target Price |
Source Source |
|
Mar 24, 2026 |
— |
Outperform |
11.00 C |
Raymond James |
|
Feb 04, 2026 |
— |
Outperform |
12.00 C |
Scotiabank |
|
Jan 26, 2026 |
— |
Outperform |
12.00 C |
RBC Capital |
|
Oct 15, 2025 |
— |
Buy |
15.00 C |
Stifel Nicolaus |
|
Sep 18, 2025 |
— |
Outperform |
15.00 C |
RBC Capital |
|
Aug 21, 2025 |
— |
Outperform |
16.00 C |
National Bank |
|
Aug 12, 2025 |
— |
Outperform |
15.00 C |
Raymond James |
|
Aug 11, 2025 |
— |
Buy |
16.00 C |
TD Securities |
|
Jul 08, 2025 |
— |
Buy |
15.00 C |
TD Securities |
|
Jun 20, 2025 |
— |
Outperform |
14.00 C |
Raymond James |
|
Jun 20, 2025 |
— |
Outperform |
14.50 C |
Scotiabank |
|
Jun 10, 2025 |
— |
Outperform |
14.00 C |
National Bank |
----------
3. Quarterly in VHI from Refinitiv as of 2025-12-31:
Revenue: $31.39 M CAD
(Year over Year change 52.45%)
Gross Profit: $24.9M
CAD (Year over Year change 48.69%)
Operating income: -$0.17M
CAD (Year over Year change -91.44%)
Net income bf tax: $0.75M
CAD (Year over Year change 333.58%)
Net income after tax:
$4.07M CAD (Year over Year change 416.68%)
Net income available
to common share: $4.07M CAD
Diluted EPS: 0.06 (Year
over Year change 342.64%)
---------------------------------
4.
Valuation measures and statistics from
Yahoo Finance
Valuation Measures
|
Current |
12/31/2025 |
9/30/2025 |
6/30/2025 |
3/31/2025 |
12/31/2024 |
|
|
Market
Cap |
514.71M |
598.81M |
700.01M |
614.10M |
566.22M |
593.03M |
|
Enterprise
Value |
398.04M |
476.73M |
621.60M |
523.67M |
510.25M |
511.95M |
|
Trailing
P/E |
81.40 |
236.75 |
138.62 |
268.24 |
169.17 |
187.83 |
|
Forward
P/E |
40.65 |
38.61 |
38.31 |
66.23 |
48.31 |
49.02 |
|
PEG
Ratio (5yr expected) |
1.18 |
-- |
-- |
-- |
-- |
-- |
|
Price/Sales |
4.50 |
5.59 |
7.48 |
8.14 |
7.54 |
8.97 |
|
Price/Book |
1.94 |
2.29 |
3.84 |
3.42 |
3.91 |
4.61 |
|
Enterprise
Value/Revenue |
3.65 |
4.86 |
7.52 |
6.98 |
7.44 |
8.31 |
|
Enterprise
Value/EBITDA |
23.34 |
31.84 |
45.49 |
42.56 |
42.87 |
39.38 |
------------------------------------------------
5.
Notes as of 2026-04-25
5.1 Latest quarter earnings report
“2025 was a milestone year for VitalHub,
surpassing $100 million in revenue. In the fourth quarter, we achieved 10%
annual organic ARR⁽¹⁾ growth and 24% adjusted EBITDA as a percentage of
revenue⁽¹⁾,” said Dan Matlow, CEO of VitalHub. “We made significant
acquisitions and filled in gaps in our portfolio that support our cross-selling
activities globally. Our adjusted EBITDA as a percentage of revenue improved
quarter over quarter as we commenced integration of the new acquisitions and we
expect to realise further improvement in 2026. We are leveraging AI in our
product roadmap and internally from a productivity perspective, as we continue
to optimize the organization as one global team. We have a strong balance sheet
as we consider acquisition opportunities of all sizes in our core and adjacent
geographies. We are excited for the year ahead.”
Fourth Quarter 2025 Highlights
ARR⁽¹⁾ as at December 31, 2025 was
$96,149,750 as compared to $93,693,789 at September 30, 2025, an increase of
$2,455,961 or 3%.
Over the previous quarter, ARR movement in
Q4 2025 from Q3 2025 was attributable to the following:
Organic growth of $1,881,405 or 2%.
Gain of $574,556 due to fluctuations in
foreign exchange rates.
Revenue of $31,390,374 as compared to
$20,590,779 in the equivalent prior year period, an increase of $10,799,595 or
52%.
Gross profit as a percentage of revenue
was 79% in Q4 2025 as compared to 81% in the equivalent prior year period.
Net income before income taxes of $750,087
as compared to $173,000 in the equivalent prior year period.
Net income of $4,067,533 as compared to
$787,244 in the equivalent prior year period.
EBITDA⁽¹⁾ of $3,285,082 as compared to
$1,875,370 in the equivalent prior year period.
Adjusted EBITDA⁽¹⁾ of $7,428,508 or 24% of
revenue, as compared to $5,046,758 or 25% of revenue in the equivalent prior
year period, an increase of $2,381,750 or 47%.
Annual 2025 Highlights
ARR⁽¹⁾ as at December 31, 2025 was
$96,149,750 as compared to $71,054,210 at December 31, 2024, an increase of
$25,095,540 or 35%.
Over the previous year, ARR movement in Q4
2025 from Q4 2024 was attributable to the following:
Organic growth of $7,231,031 or 10%.
Acquisition growth of $15,870,000 or 22%.
Gain of $1,994,509 due to fluctuations in
foreign exchange rates.
Revenue of $108,966,918 as compared to
$68,594,310 in the equivalent prior year period, an increase of $40,372,608 or
59%.
Gross profit as a percentage of revenue
was 80% compared to 81% in the prior year.
Net income before income taxes of
$5,901,401 as compared to $5,895,758 in the equivalent prior year period.
Net income of $6,110,963 as compared to
$2,999,045 in the equivalent prior year period
EBITDA⁽¹⁾ of $14,634,782 as compared to
$9,950,872 in the prior year.
Adjusted EBITDA⁽¹⁾ of $26,554,099 or 24%
of revenue, as compared to $17,840,272 or 26% of revenue in the equivalent
prior year period, an increase of $8,713,827 or 49%.
Cash on hand and short-term investments as
at December 31, 2025 was $119,180,625 compared to $56,574,904 as at December
31, 2024.
5.2 Personal Notes
Its revenue is higher than $100M and recently signed a
contract with Ontario government arm. “This large-scale deployment of our
technology builds on years of successful implementations across Ontario and
beyond. My colleagues and I are proud to partner with Ontario Health on such an
innovative provincial initiative,” said John Sinclair, President & CEO,
Novari. https://www.secure.bmoinvestorline.com/wealth/journeys/app/shell/research/US/AAPL/1774463577086
It is good to diversify our portfolio in other sectors
of economy or technologies. VHI.TO is in health care environment and has a contract
with Ontario government.
6.
From Morningstar report
Valuation as of 23 Apr 2026
Vitalhub Corp is assigned a 5-star quantitative star rating,
illustrating our stance that this share class offers a compelling opportunity
for investors. The stock currently trades at a 27% discount to our quantitative
fair value estimate of 10.81 CAD per share; however, caution is warranted due
to this estimate's high uncertainty rating.
The firm's solid growth bolsters our estimated fair value.
Consistent revenue and earnings growth indicates a company's potential for
increased market share and profitability. Reflecting the firm's growth is its
revenue 3-year growth of 39.7%, which ranks in the top 10% compared with peers
globally. Robust trailing three-year revenue growth portends a favorable future
trajectory, which contributes to ourview that shares are cheap.
Alternatively, the company's unfavorable dividend structure
is potentially concerning. Dividends represent a stable form of future cash
flows returned to shareholders, and low dividend payments can increase the
perceived risk of a business. The firm's forward dividend yield of 0%, for
example, lies in the bottom 30% compared with peers globally. This could imply
a planned dividend cut or relatively high share price, which, despite our
favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model
considers momentum as part of its comprehensive analysis. This share class has
been a laggard relative to the broader diverse over the past year.
This underperformance makes the stock appear cheap,
which portends a buying opportunity in light of other contributors to our
model.
No comments:
Post a Comment